



South San Francisco, CA

Apr 13<sup>th</sup> 2020

Dear Colleagues,

All of us at Atara want to take a moment to thank **ASTS** and your members for your dedication and continued expertise in this trying and evolving COVID-19 (coronavirus) pandemic. We recognize that this time is especially difficult for health care providers, their institutions and patients due to the increased demands for patient care. We want to emphasize that our priority remains ensuring the health and safety of patients, caregivers, and site staff.

While we announced last week that we are temporarily pausing screening and enrollment in our phase 1b study of ATA188 for multiple sclerosis (MS), we are continuing to enroll patients in our phase 3 study of tabellecleucel in Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV<sup>+</sup> PTLD). We remain committed to help patients in need with EBV-driven cancers, where appropriate. Please see our press release (<https://www.businesswire.com/news/home/20200402005242/en/Atara-Biotherapeutics-Update-Context-COVID-19-Pandemic>).

In addition to Atara's policies for protecting our staff, we are closely following local and national guidelines. We would like to share what has been implemented to protect product safety:

- Availability of Atara's investigational off-the-shelf, allogeneic EBV T cells is unchanged and we are experiencing no issues with supply as a result of the current COVID-19 situation.
  - Prior to the COVID-19 outbreak, we manufactured significant inventories of tabellecleucel, process intermediates, and required starting materials to maintain long-term supply across tabellecleucel, ATA188, and other programs.
  -
- Distribution and logistics activities remain active at our network of manufacturing and distribution sites and we plan to continue to serve clinical trial and compassionate use patients. We are in close communication with transportation vendors as well to ensure no disruption.
- Our off-the-shelf, investigational allogeneic T-cell immunotherapy is manufactured from healthy donors that are rigorously screened and tested for infectious diseases. In addition, all our current inventory supporting clinical trials was collected from healthy donors in the U.S. prior to November 2019.
- Atara is also closely following recently issued regulatory agency guidelines for clinical trials to ensure patient safety and continued availability of our investigational products.

Thank you again for your dedication, partnership and support during this unprecedented time. Please do not hesitate to get in touch with me or any of your Atara contacts with any questions or concerns. We sincerely hope you, your staff, families, and patients stay safe.

Sincerely,

A handwritten signature in black ink, appearing to read "C. Langer". The signature is written in a cursive style with a large initial "C" and a long, sweeping underline.

Christiane Langer, MD  
SVP, Head of Global Medical Affairs  
Atara Biotherapeutics  
Email: [Clanger@atarabio.com](mailto:Clanger@atarabio.com)  
Phone: 650-291-4593